BCMA, a target marker for multiple myeloma (MM), can be cleaved by γ-secretase (GS), reducing its surface density and generating soluble molecules that can bind to CAR receptors, thus limiting the efficacy of BCMA-targeted CAR-T cell therapy [38]. This evidence concerns the gene TNFRSF17 and plasma cell myeloma.